Of note, the combination of S63845 with either selective BCL-2 or BCL-XL inhibitor also resulted in synergistic reduction in cervical cancer cell growth and invasion [41], increased apoptotic response in AML cell lines and primary samples [36], and exerted profound synergistic activity against T-cell acute lymphoblastic leukemia cells (T-ALL) in vitro and in vivo in a T-ALL zebrafish embryos model [42]. This evidence concerns the gene BCL2L1 and acute lymphoblastic leukemia.